Product image of Linagliptina Krka (Linagliptin) supplied by GNH India

Linagliptina Krka

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptina Krka (Linagliptin)

Linagliptin, the active ingredient in Linagliptina Krka, is a DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control when combined with diet and exercise.

GNH India supplies Linagliptina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is used within the antidiabetic drug class to manage blood glucose levels in patients with type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): provides glycaemic control as a single oral agent.
  • Type 2 diabetes mellitus (combination therapy): used together with metformin, sulfonylureas or insulin to enhance glucose‑lowering effects.
  • Type 2 diabetes mellitus (renal impairment): can be administered without dose adjustment in patients with moderate to severe renal dysfunction.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion and suppress glucagon release, leading to reduced post‑prandial and fasting plasma glucose concentrations.

Side Effects

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract infection symptoms.
  • Headache: transient mild to moderate headache.
  • Gastrointestinal discomfort: includes nausea, abdominal pain or dyspepsia.
  • Dizziness: occasional light‑headed sensation.
  • Fatigue: feeling of tiredness without obvious cause.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention.
  • Severe hypersensitivity reactions: including rash, angioedema or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: rare autoimmune skin blistering disorder.
  • Acute renal failure: abrupt decline in kidney function, though rare with linagliptin.

Precautions & Warnings

Before initiating linagliptin therapy, consider the following safety measures.

  • Renal function: no dose adjustment required, but monitor renal parameters in severe impairment.
  • Hepatic impairment: use with caution and assess liver enzymes regularly.
  • Hypersensitivity: discontinue if signs of rash, swelling or anaphylaxis develop.
  • Pregnancy: safety not established; avoid unless benefits outweigh risks.
  • Elderly patients: monitor for hypoglycaemia when combined with insulin or sulfonylureas.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong P‑gp inhibitors (e.g., itraconazole, clarithromycin): may increase linagliptin exposure.
  • Insulin or sulfonylureas: combined use can precipitate severe hypoglycaemia.
  • Rifampin: enzyme induction may reduce linagliptin plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may affect glucose homeostasis, requiring glucose monitoring.

  • ACE inhibitors or ARBs: monitor blood pressure and renal function.
  • Warfarin: occasional reports of altered INR; check coagulation parameters regularly.

Frequently Asked Questions

Linagliptina Krka contains linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It helps lower blood glucose levels when used together with diet and exercise, either as a single agent or in combination with other antidiabetic medicines.

Linagliptin works by selectively blocking the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, resulting in improved glycaemic control.

The specific dose of Linagliptina Krka is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same mechanism of action as other DPP‑4 inhibitors but is unique because it is primarily eliminated via the entero‑hepatic route, allowing use without dose adjustment in renal impairment. Its safety and efficacy profile is comparable to agents such as sitagliptin or saxagliptin.

Linagliptina Krka tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events, although rare, include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, hepatic injury, and bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or jaundice.

Linagliptina Krka should be avoided in individuals with known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is advised for patients with a history of pancreatitis, severe hepatic disease, or those taking medications that may cause significant drug‑drug interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT